AbCellera gains as experimental drug reduces hot flashes in mid-stage trial
BUZZ-AbCellera gains as experimental drug reduces hot flashes in mid-stage trial Updates
** Shares of AbCellera ABCL.O rise ~36% to more than three-year high of $9.41
** Stock set for best day on record, if gains hold
** Co says a mid-stage trial showed its experimental drug significantly reduces the frequency and severity of moderate-to-severe hot flashes at four weeks versus placebo after a single dose
** ABCL635 is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms, commonly known as hot flashes, due to menopause
** Including session's moves, stock up 165% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce